[Form 4] GALECTIN THERAPEUTICS INC Insider Trading Activity

Rhea-AI Filing Summary

Galectin Therapeutics Inc. (GALT) reported insider transactions by its President and CEO, who is also a director. On November 17, 2025, the executive exercised stock options to buy 15,680 shares of common stock at $2.39 per share and sold the same number of shares at a weighted average price of $6.0359. On November 18, 2025, the executive similarly exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511. After these transactions, the executive directly owned 832,592 common shares and indirectly held 2,000 shares as custodian for a minor child. The filing notes that the trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on April 17, 2025, and that the options exercised had vested fully on December 14, 2018.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEWIS JOEL

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		M(1)		15,680	A	$2.39	848,272	D
Common Stock	11/17/2025		S(1)		15,680	D	$6.0359(4)	832,592	D
Common Stock	11/18/2025		M(1)		6,783	A	$2.39	839,375	D
Common Stock	11/18/2025		S(1)		6,783	D	$6.1511(5)	832,592	D
Common Stock								2,000	I	as USTA custodian for a minor child(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.39	11/17/2025		M(1)			15,680	12/14/2018(2)	12/14/2027	Common Stock	15,680	$0	6,783	D
Stock option (right to buy)	$2.39	11/18/2025		M(1)			6,783	12/14/2018(2)	12/14/2027	Common Stock	6,783	$0	0	D

Explanation of Responses:

1. The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025.

2. The options vested 100% on December 14, 2018.

3. These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

4. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. The shares were sold in multiple transactions at prices ranging from $6.00 to $6.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

	Jack W. Callicutt, by power of attorney	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did GALT report in this Form 4?

The President and CEO of Galectin Therapeutics Inc. (GALT) exercised stock options and sold the resulting shares on two dates. On November 17, 2025, they exercised options for 15,680 shares at $2.39 and sold those shares at a weighted average price of $6.0359. On November 18, 2025, they exercised options for 6,783 shares at $2.39 and sold those shares at a weighted average price of $6.1511.

How many GALT shares does the reporting person own after these transactions?

Following the reported transactions, the executive directly owned 832,592 shares of Galectin Therapeutics common stock. In addition, they had indirect ownership of 2,000 shares held as custodian for a minor child under the Uniform Transfer to Minors Act.

Were the GALT insider trades made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as previously disclosed in the company’s Quarterly Report on Form 10-Q filed on August 14, 2025.

What were the exercise and sale prices for the GALT stock options?

The stock options had an exercise price of $2.39 per share. Shares sold on November 17, 2025 had a weighted average sale price of $6.0359, based on trades between $6.00 and $6.10. Shares sold on November 18, 2025 had a weighted average sale price of $6.1511, based on trades between $6.00 and $6.32.

What is disclosed about the GALT stock options exercised in this Form 4?

The derivative securities were stock options (right to buy) with an exercise price of $2.39 per share. They became exercisable on December 14, 2018 and have an expiration date of December 14, 2027. The options exercised in these transactions were fully vested and, after the reported exercises, the number of such options beneficially owned was shown as 0.

How does the reporting person treat the indirectly held GALT shares for ownership purposes?

The 2,000 indirectly held shares are recorded in the name of the reporting person as custodian for a minor child under the Uniform Transfer to Minors Act. The reporting person disclaims beneficial ownership of these securities, and the filing notes that it is not an admission of beneficial ownership for Section 16 or any other purpose.